



100TH PATIENT ENROLLED IN INTERNATIONAL TRIAL OF MICROVENTION'S HYDROCOIL® EMBOLIC SYSTEM

Enrollment On Schedule in Physician-Designed HELPS Trial Comparing MicroVention System to Current Standard Therapy for Treating Cerebral Aneurysms

ALISO VIEJO, Calif. – August 2, 2005 – MicroVention, Inc., a leading developer, manufacturer and marketer of minimally invasive treatments for cerebral and peripheral vascular diseases, announced today that the 100th patient was enrolled in the independent, physician-designed and managed, international trial of its HydroCoil® Embolization System (HES) for treating cerebral aneurysms, which are potentially deadly bulges or sacs in the wall of an artery in the brain.

An expected total of 500 patients at more than 20 sites around the world will ultimately make up the prospective, blinded, randomized trial titled HydroCoil Endovascular Aneurysm Occlusion and Packing Study (HELPS). The head-to-head trial will compare the results derived from the HydroCoil system to results from any approved bare platinum coils, currently considered the mainstay of endovascular aneurysm therapy.

The trial is based in the United Kingdom where it is sponsored by the Lothian Health Board and supported by the UK's National Health Service. Physicians in the U.S., France and Germany are also participating and Philip White, M.D., of Western General Hospital in Edinburgh, is the study's chief investigator.

"We have reached the 100-patient enrollment milestone, which represents a major achievement in the short time the trial has been running. I believe this is due to the high level of interest that has been generated among the physician community in participating in the clinical trial," Dr. White said. "This trial was designed by physicians who know first-hand the challenges they face treating cerebral aneurysms. Thanks to our progress on enrollment, we hope to be able to provide periodic updates and preliminary results much more quickly."

Mike Kleine, President and CEO of MicroVention, said he's confident that the Hydrocoil technology will continue to prove its clinical value as a more durable solution for endovascular occlusion of aneurysms in a head-to-head trial such as HELPS. HydroCoil is designed to combine the features of greater space filling and improved healing of a microporous expandable hydrogel with the delivery and handling characteristics of a detachable platinum coil.

"When this trial concludes with the kind of results we expect it will produce, we believe it has the potential to change the market and position our Hydrocoil system as the gold standard," Kleine said. "That's why we are working so closely with a wide variety of physicians on HELPS and why we wanted physicians to actually design the protocol of the trial itself. This allows our product to actually prove its value among the physicians who will be using it in a clinical setting."

About the HES Procedure

The HydroCoil Embolic System is a unique endovascular embolization device combining the company's platinum microcoil technology with a proprietary, highly expandable microporous hydrogel called Intelligel. The Intelligel polymer is a responsive or "smart biomaterial" that does not swell until a period of contact with blood. This responsiveness gives physicians the ability to precisely control delivery of the device and allows for repositioning if necessary. When the hydrogel swells, it provides improved filling of the aneurysm. HydroCoil combines the safety and ease of use of platinum coils with the filling and mechanical stability properties of the hydrogel. HydroCoil offers a new therapeutic alternative to the current treatment choices of platinum coil embolization and neurosurgical clipping, and is also being used clinically to treat fistula and peripheral vascular aneurysms.

About MicroVention, Inc.

MicroVention, Inc. (www.microvention.com) is a privately held medical-device company dedicated to the development and commercialization of new catheter-based technologies for the endovascular treatment of peripheral and cerebral vascular diseases. The company has received 510(k) clearance and CE Mark for both its HydroCoil Embolic System and the MicroPlex® Coil System to treat cerebral aneurysms and other vascular lesions. MicroVention sells its products through its direct sales force in the U.S., Canada, France, Germany and the United Kingdom and through distributors in numerous other countries.

MicroVention Contacts:

Michael Kleine, President, CEO
William Hughes, Vice President, CFO
Ph. 949-461-3314
Fx. 949-461-3329

Matt Clawson (Media)
Allen & Caron, Inc.
Ph. 949-474-4300
Fx. 949-474-4330